In a nutshell
This study reviewed the effectiveness and safety of cabergoline (Caberlin / Dostinex) for reducing the risk of ovarian hyperstimulation syndrome among women receiving ovarian stimulation drugs during the course of fertility treatments.
Some background
Ovarian hyperstimulation syndrome is one serious potential complication of drugs used for ovarian stimulation. The syndrome is characterized by painful ovarian enlargement due to the formation of multiple ovarian cysts. Eventually, ovarian hyperstimulation syndrome causes wide-spread damage and may become life-threatening. Therefore, the prevention of ovarian hyperstimulation syndrome during fertility treatments is paramount. Cabergoline has been noted to reduce the risk of ovarian hyperstimulation syndrome in previous studies.
Methods & findings
This meta-analysis (an analysis of data combined from several similar studies) reviewed seven studies investigating the use of cabergoline during ovarian stimulation therapy.
The analysis found significant benefits with the use of cabergoline during ovarian stimulation therapy. Among the 408 women receiving cabergoline, only 46 developed ovarian hyperstimulation syndrome. This compared to 127 cases of ovarian hyperstimulation syndrome noted among 450 women undergoing ovarian stimulation without cabergoline.
The bottom line
This study concluded that cabergoline reduces the risk of developing ovarian hyperstimulation syndrome during controlled ovarian stimulation.
What’s next?
Consult with your physician regarding the prevention of ovarian hyperstimulation syndrome during fertility treatments.
Published By :
Fertility and Sterility
Date :
Dec 18, 2013
The article gives a lot of information as I am on OCP3 almost for the last 3 months. My Prolactin level raised to 207 and I am a patient of Hypothyroidism. From my early 30s, I have taken Cabergoline 0.5mg twice a week along with OCP3. So may I start this dosage to reduce Prolactamia